The study enrolled 9,000 patients aged 50 years or older and randomized half to Flublok Quadrivalent influenza vaccine and the other half to quadrivalent inactivated influenza vaccine produced in eggs.
Study data showed Flublok protected 33% more patients than the egg-derived vaccine. Flublok produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.
Flublok is a pure influenza vaccine that does not contain egg proteins, preservatives, antibiotics, gelatin, or latex. In traditional egg-based vaccines, mutations are sometimes introduced during the process of egg adaptation that can cause the vaccines to be ineffective.
The trivalent Flublok vaccine contains three times more antigen than traditional flu vaccines (3 or 4x45mcg hemagglutinin protein versus 3 or 4x15mcg hemagglutinin protein for trivalent or quadrivalent vaccine, respectively). It is currently approved for people aged 18 years and older to prevent influenza disease.
This article originally appeared on MPR